TrianglePembrolizumab (NCT07808151)
Pembrolizumab trial for Colon Cancer (NCT07808151). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with removable T3 or T4 colon adenocarcinoma that has not spread distantly and is mismatch-repair proficient and microsatellite stable. Previous checkpoint immunotherapy or an urgent need for surgery excludes participation.
The idea: give pembrolizumab and porustobart before surgery to release immune brakes. Both groups receive two pembrolizumab doses; random assignment determines one or two porustobart doses. Surgery follows six to nine weeks after treatment starts. Researchers examine remaining cancer and side effects.
This phase 2 study plans 100 patients. Solstice Oncology sponsors three recruiting US locations.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.